0001396814-24-000013.txt : 20240104 0001396814-24-000013.hdr.sgml : 20240104 20240104172439 ACCESSION NUMBER: 0001396814-24-000013 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240102 FILED AS OF DATE: 20240104 DATE AS OF CHANGE: 20240104 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SLONIN JONATHAN CENTRAL INDEX KEY: 0001875723 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35060 FILM NUMBER: 24513366 MAIL ADDRESS: STREET 1: C/O PACIRA BIOSCIENCES, INC. STREET 2: 5401 WEST KENNEDY BOULEVARD, SUITE 890 CITY: TAMPA STATE: FL ZIP: 33609 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Pacira BioSciences, Inc. CENTRAL INDEX KEY: 0001396814 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 510619477 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 5401 WEST KENNEDY BOULEVARD STREET 2: SUITE 890 CITY: TAMPA STATE: FL ZIP: 33609 BUSINESS PHONE: 813-553-6680 MAIL ADDRESS: STREET 1: 5401 WEST KENNEDY BOULEVARD STREET 2: SUITE 890 CITY: TAMPA STATE: FL ZIP: 33609 FORMER COMPANY: FORMER CONFORMED NAME: Pacira Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20101029 FORMER COMPANY: FORMER CONFORMED NAME: PACIRA INC DATE OF NAME CHANGE: 20080318 FORMER COMPANY: FORMER CONFORMED NAME: Blue Acquisition Corp DATE OF NAME CHANGE: 20070418 4 1 wk-form4_1704407065.xml FORM 4 X0508 4 2024-01-02 0 0001396814 Pacira BioSciences, Inc. PCRX 0001875723 SLONIN JONATHAN C/O PACIRA BIOSCIENCES, INC. 5401 WEST KENNEDY BOULEVARD, SUITE 890 TAMPA FL 33609 0 1 0 0 Chief Medical Officer 0 Common Stock 2024-01-02 4 A 0 5000 0 A 51196.475 D Stock Option (Right to Buy) 32.07 2024-01-03 4 A 0 10000 0 A 2034-01-03 Common Stock 10000 10000 D Represents restricted stock units that vest in four equal annual installments beginning on January 2, 2025, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Includes 311.535 shares of common stock acquired under the issuer's employee stock purchase plan in December 2023. The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. /s/ Kristen Williams, Attorney-in-Fact 2024-01-04